Open Targets Genetics

Bruno Ariano is a senior bioinformatician in the Open Targets Genetics team.

His main work consists in maintaining and developing the pipelines included in the Genetics portal. In collaboration with the other members of his team, Bruno is also focused on applying novel methods to find causal variants involved in diseases.

He obtained a PhD in genetics at Trinity College Dublin in 2022. During this experience Bruno specialized in imputing low coverage genomes and investigating the fine-structure and complex traits in ancient European populations.

Daniel studied genetics at Queen Mary University of London (BSc) before attending Cambridge to complete his MPhil in Epidemiology. As a bioinformatician his research has involved looking at how gene and protein expression data can be leveraged to better understand breast and ovarian cancer.

As a computational biologist within the Open Targets Genetics team, his work involves the incorporation of new data sources and analyses to assist in drug target discovery.

Ricardo Esteban Martinez Osorio is a full stack developer working across the Open Targets Platform and Genetics teams.

Jack has a background is in mathematics (BSc) and computational biology (MPhil). His PhD project was focused on the functional genomics of Rheumatoid arthritis, exploring cell-type specific functions underlying existing GWAS associations.

As a statistical geneticist in the Open Targets Genetics team, Jack currently focuses on developing and integrating tissue enrichment analysis for all publicly available GWAS into the Genetics portal.

Maya obtained her PhD in Molecular Genetics and Epidemiology from the Pasteur Institute in Lille, during which she worked on the identification and functional characterization of genetic variants of predisposition to Obesity and Type 2 Diabetes in the French population.

She then joined the University of Cambridge. Using Genome Wide Association Studies, she identified new regions in the human genome associated with cancer, and causative variants within these regions, furthering our understanding of how such variants affect cancer susceptibility and pathogenesis.

Maya joined Open Targets, where she leads the Genetic Analysis team, focusing on using human genetics and functional genomics data to guide therapeutic target identification and prioritisiation, inform drug repositioning and predict toxicity effects.

Yakov obtained his PhD in Statistical Genetics from Novosibirsk State University. He worked on the developing approaches for studying non-additive models and applied them to study the genetics of human metabolome.

In 2018, Yakov became a group lead in the Institute of Cytology and Genetics SB RAS. His research focus was the development of new multivariate approaches and rare variant analysis approaches and its application to study the genetics of human lifespan, back pain and varicose veins.

Yakov joined Open Targets in 2022 as part of the Genetics core team to integrate novel genetic approaches for better prediction of drug targets.